In the domain of oncology, there has been considerable interest in the central nervous system reaction to Osimertinib, a third-generation tyrosine kinase inhibitor.This study aims to provide insight into the effectiveness and safety of treatments, including a comparison of the central nervous system reaction to Osimertinib versus conventional treatment, in patients with progressive non-small cell lung cancer (NSCLC).

Four critical aspects of this comparison will be discussed in the subsequent sections: therapeutic effectiveness, side effects, patient well-being, and death rates.In treating NSCLC with EGFR mutations, including those with central nervous system metastases, Osimertinib has demonstrated exceptional effectiveness.Compared to conventional treatment, Osimertinib has resulted in enhanced objective response ratios (ORRs) and disease-free survival (PFS) among patients with central nervous system involvement.

While it has proven to be effective, osimertinib has associated side effects that need to be considered.A key aspect of cancer therapy is patient well-being.This section will examine the effect on patient well-being resulting from therapies with osimertinib and conventional treatment, focusing on elements such as mental function, tiredness, and overall well-being.

The primary objective of cancer therapy is the improvement of total survival rates.This article will provide a detailed study of the central nervous system reaction to osimertinib versus conventional treatment in non-small cell lung patients with cancer, by considering these four main points.